The Readout Loud
339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad
Jan 30, 2025
Rachel Korsdreng, STAT’s chief Washington correspondent, dives into the hot-button issues surrounding RFK Jr.'s contentious confirmation hearings. She sheds light on intense exchanges about vaccines and autism, particularly with senators like Bernie Sanders. The conversation also covers a groundbreaking study on reversing cirrhosis in patients with MASH, critiques of a provocative obesity ad, and innovative funding approaches in biotech aimed at tackling ALS. A fascinating mix of politics and healthcare advancements!
34:29
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The groundbreaking study by Akero Therapeutics reveals the potential to reverse cirrhosis in severe MASH patients, indicating significant treatment advancements.
- RFK Jr.'s confirmation hearings raised critical concerns about his controversial views on vaccines and his understanding of key health policies.
Deep dives
Breakthrough in MASH Treatment
Akiro Therapeutics announced significant progress in the treatment of MASH, previously known as NASH, with promising results showing reversal of cirrhosis in severe patients. This marks a groundbreaking advancement, given that reversing damage from cirrhosis was thought to be impossible. Unlike earlier therapies targeting less severe stages, Akiro's study demonstrates the potential for late-stage MASH patients to regain liver function. The upcoming phase three study will further assess long-term benefits, including potentially reducing the need for liver transplants.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
